header logo image


Page 17«..10..16171819..30..»

Archive for the ‘Genetic Engineering’ Category

Land scarcity and disease threaten a multifaceted indigenous crop in Ethiopia – Mongabay.com

Wednesday, May 20th, 2020

SIDAMA, Ethiopia For Lidya Ashango and 14 million other Ethiopians, the false banana plant widely known as enset is a staple food and, on many occasions, a supplementary source of income. But its no longer easy to grow this crop in the southern part of the country, where land is scarce and plant disease is inevitable.

A mother of seven living in this southern town of Sidama, Ashango and her family have been growing, harvesting and processing enset as long as she can remember.

Men plant the crop, but the women do the time-consuming and laborious work of producing food from the crop. By the time a well-tended crop is ready to harvest, three to four years after planting, the woman goes to the farm with a machete and cuts the false stem to scrape and separate it into a starchy pulp and a fiber.

The pulp is covered with enset leaves and left in a pit to ferment for months before being used to make various bread and porridge dishes. Kocho,the fermented product to turn into bread, and bulla,the flour to be cooked into porridge, are among the dishes prepared by the women from the plant. The leaves are used for livestock feed and packaging.

Although enset varieties are known to be found in other countries in Africa such as Uganda, this cultivation and fermentation process is largely known only to Ethiopians with traditional indigenous knowledge. Gurage, Sidama, Gedeo and Hadiya are a few of the ethnic groups that grow and depend on this perennial crop.

Ensets label as a tree against hunger was adopted in 1984, when the northern part of Ethiopia thats mainly dependent upon cereals like teff was severely hit by drought and famine. Researchers note that the south, which relies on enset, saw no such tragedy; and also that the tree is relatively resistant to climate change and exists in hundreds of varieties.

Unlike other cereals, it can also be intercropped with coffee or other fruit-bearing trees, still providing a higher yield per unit area.

However, despite ensets popularity, rapid population growth in Ethiopia has put pressure on available land, and farmers seeking more income are turning toward cash crops like khat, a stimulant, and maize.

Less land means less livestock and less manure for the plant, said Beyene Teklu in an interview. Teklu has been researching farming systems in Ethiopia, especially enset, for the past six years.

According to a study he did on 240 farms in Sidama and Gedeo, khat-based farms grew by 21% between 1991 and 2013, whereas enset-based farming showed a decline of 13% during this period.

But the intensive production of cash crops like khat and maize can only be good for the first three or four years. After that, land that was left empty for several months after harvesting will be eroded and the nutrients gone, resulting in a very low yield the next harvest.

Teklu says this will in turn force youths to abandon the farms and leave for cities, which are growing increasingly crowded with jobseekers.

Beyond land scarcity, the other threat to enset is its high vulnerability to mealy bugs and diseases like bacteria wilt, which dry up its leaves and eventually kill the whole plant.

Recent reports by the U.S. Department of Agriculture show that Ethiopian researchers, in collaboration with the International Institute of Tropical Agriculture (IITA), have used genetic engineering to produce a modified enset thats resistant to bacteria wilt.

However, scholars like Teshome Hunduma, a Ph.D. research fellow at the Norwegian University of Life Sciences, looks at the initiative with a critical eye.

In an article for the local news site Addis Standard in April, Hunduma said there are no independent studies that show improved yield, disease-resistance or socioeconomic benefits for smallholder farmers from the use of genetically modified crops. An attempt to genetically modify and release enset for commercialization requires a high-level of precaution, he wrote.

An orphan crop thats been neglected by the government for several years, ensets future lies in long-term strategies that apply beyond five or 10 years, according to experts like Tekle.

Banner image: Ashangos brother-in-law, Dilke Didamo, 38, is portrayed at the familys enset farm in Sidama, Ethiopia. Photo by Maheder Haileselassie Tadese.

See original here:
Land scarcity and disease threaten a multifaceted indigenous crop in Ethiopia - Mongabay.com

Read More...

Technology In A Time Of Crisis: How DARPA And AI Are Shaping The Future – Forbes

Wednesday, May 20th, 2020

December 31, 2019 is a day that will live in infamy. On this day, a pneumonia of unknown origin in the Hubei province of China was reported to the World Health Organization (WHO). We did not know it then, but this would be the day that the world would change. At the time of writing this article, there have been more than 4 million confirmed cases and nearly 300,000 confirmed deaths worldwide.

This global enemy, which we have learned to call COVID-19, has ravaged lives, regardless of age, creed or socioeconomic status. It has caused economic turmoil and has disrupted the lives of almost every human across the globe.

The impact that an entity approximately 120 nanometers in diameter -- approximately 1/100th the diameter of a human hair -- can have on the world is remarkable. But as indelible a mark as the virus has had, so too has been the call to arms by the scientific community. Every generation tends to be called to rise to a great challenge, and the response of this generation of scientists, technologists, engineers and mathematicians will shape the future of humanity and health more than SARS-CoV-2 itself.

As mentioned in a recent article on Forbes, the mobilization of biotechnology is similar to the allies storming the beaches on D-Day. Just like that fateful day, the attack on coronavirus is multipronged. There are new-generation vaccine methods, such as synthetic peptide-based vaccines and nucleic acid-based vaccines, that are genetically engineered. Retrovirals, diabetic medications, immunologic drugs, antibiotics and even anticoagulants have all been proposed to combat the pandemic. By the last count, over 250 medications are being evaluated at various stages.

Before the Defense Research Advanced Projects Agency's (DARPA) support of this work in 2011, the concept of engineering vaccines into DNA strands was at the edge of science. This allows the immune system to generate proteins directly. Prior to this, conventional vaccines were created by inducing an immune response by introducing antigens into the body. Now, many of the vaccines that are being evaluated are using the more novel approach, including Modernas vaccine, the first to enter phase one human trials, and Inovios vaccine, scheduled to enter trials this summer.

But newer, even more audacious biotechnological solutions are currently underway by DARPA in a project they're calling COVID-19 Shield, as part of the Pandemic Protection Platform. The cutting-edge concept is to harvest B cells from survivors of the disease and replicate and mass produce them via genetic engineering. This concept, if successful, could potentially mitigate any future potential pandemic in a matter of weeks and allow time for a vaccine to be developed while maintaining a flat infection curve.

However, DARPA is not the only group actively seeking solutions. There are myriad others, including the Biomedical Advanced Research and Development Authority (BARDA), which is seeking both low and high technology readiness level (TRL) solutions through a broad agency announcement (BAA). This includes a large vaccine contract with J&J worth over $1 billion andfast-tracking an IL-6 inhibitor by Actemra that could mitigate the lung manifestations of COVID-19.

This joins several other immune-mediated drug therapies to attempt to ameliorate the suspect cytokine storm cascade that occurs in more severe cases. BARDA is also reviewing advances from the pinnacle of bioengineering by exploring the use of extremophiles for drug therapies.

Biologic countermeasures are, however, not the only weapons being developed in this new viral war. Artificial intelligence (AI) is also playing a role to combat the novel coronavirus. AI is helping to mitigate the spread of disease, find therapies and aid in treatment strategies. BlueDot was the first to use its AI application to identify a novel pneumonia outbreak in China.

Then there is the COVID-19 Open Research Dataset (CORD-19),a multi-institutional initiative that includes The White House Office of Science and Technology Policy, Allen Institute for AI, Chan Zuckerberg Initiative (CZI), Georgetown Universitys Center for Security and Emerging Technology (CSET), Microsoft, and the National Library of Medicine (NLM) at the National Institutes of Health (NIH).

The goal of this initiative is to create new natural language processing and machine learning algorithms to scour scientific and medical literature to help researchers prioritize potential therapies to evaluate for further study. AI is also being used to automate screening at checkpoints by evaluating temperature via thermal cameras, as well as modulations in sweat and skin discoloration. What's more, AI-powered robots have even been used to monitor and treat patients. In Wuhan, the original epicenter of the pandemic, an entire field hospital was transitioned into a smart hospital fully staffed by AI robotics.

Any time of great challenge is a time of great change. The waves of technological innovation that are occurring now will echo throughout eternity. Science, technology, engineering and mathematics are experiencing a call to mobilization that will forever alter the fabric of discovery in the fields of bioengineering, biomimicry and artificial intelligence. The promise of tomorrow will be perpetuated by the pangs of today. It is the symbiosis of all these fields that will power future innovations.

December 31, 2019 is a day that will always be remembered. Currently, the day is known as the beginning of a disruption to our lives that few -- if any -- have ever experienced, but none shall ever forget. However, as time passes and life begins anew, I believe it will be remembered for a different reason. It will be remembered as the day science and technology went to war. A day in which humanity united to unleash the full capacity of scientific innovation on an enemy that was indiscriminate to race, religion or creed. And on that fateful day, in our darkest hour, science shined brightest. And in science we trust.

Read the original here:
Technology In A Time Of Crisis: How DARPA And AI Are Shaping The Future - Forbes

Read More...

How Covid-19 Is Transforming the Biohacking Industry? Major Key Players: Thync Global Inc., Moodmetric, InteraXon Inc., Behavioral Tech., Fitbit,…

Wednesday, May 20th, 2020

Biohacking Market (Type - Inside Biohacking, and Outside Biohacking; Product - Smart Drugs, Strains, Sensors, and Other Products; Application - Genetic Engineering, Forensic Science, Diagnosis and Treatment, Synthetic Biology, Drug Testing, and Other Applications; End-user - Forensic Laboratories, Pharmaceutical and Biotechnological Companies, and Other End-users): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025. The global biohacking market is projected to grow at a CAGR of 19.2% over the forecast period of 2019-2025.

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 05/20/2020 -- Infinium Global Research has recently published a global report on "Biohacking Market (Type - Inside Biohacking, and Outside Biohacking; Product - Smart Drugs, Strains, Sensors, and Other Products; Application - Genetic Engineering, Forensic Science, Diagnosis and Treatment, Synthetic Biology, Drug Testing, and Other Applications; End-user - Forensic Laboratories, Pharmaceutical and Biotechnological Companies, and Other End-users): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025." According to the report, the global biohacking market is projected to grow at a CAGR of 19.2% over the forecast period of 2019-2025.

To Know More Request Sample of this Report@ https://www.infiniumglobalresearch.com/reports/sample-request/18407

Increasing Demand for Smart Devices and Effective Drugs

The increasing demand for smart devices and effective drugs contributes to the growth of the biohacking market. Biohacking is a new frontier in the development of drugs and therapeutics due to the emerging healthcare industry and social movement. The rising prevalence of chronic diseases led to the surge in demand for biohacking. As per the World Health Organization, it is projected that by 2020, chronic diseases account for almost three-quarters of all deaths globally.

Growing Awareness About Biohacking

The growing geriatric population boosts the expansion of the biohacking market. A study estimated that around 8.5 percent of people globally are aged 65 and over and it is projected to reach around 17 percent of the world's population by 2050. The geriatric population is prone to chronic diseases escalating the demand for biohacking. Further, growing awareness about biohacking stimulates the growth of the market. Biohacking labs are set up in garages, warehouses, with second-hand equipment bought online.

Thus, anyone interested in science can perform experiments and learn by doing. The rise in the use of radiofrequency identification technology in medical devices aligned with the penetration of the internet of things in healthcare promotes the expansion of the biohacking market. Additionally, increasing the inclusion of fitness and consumer electronics leverages the growth of the market.

Advancement in Technologies Creates Several Opportunities

The rise in demand for biohacking devices in key application areas such as forensic science, genetic engineering, drug testing, synthetic biology, and others leverages the growth of the biohacking market. On the flip side, lack of funds required for research, lack of expertise hinders the growth of the biohacking market. Moreover, advancement in technologies creates several opportunities for the growth of the biohacking market.

"We are Now Including the Impact Analysis of the COVID-19 on this Premium Report and the Forecast Period of this Report Shall be Revised to 2020-2026. The Section on the Impact of COVID-19 on Biohacking Market is Included in the Report for Free."

North America is Anticipated to Have the Largest Share

Geographically, the global biohacking market is divided into North America, Asia-Pacific, Europe, and the Rest of the World. North America is anticipated to have the largest share in the global biohacking market. The presence of key market players in the United States drives the growth of the biohacking market in North America. The increasing awareness about biohacking among the younger generation in North America led to the development of the market in the region. Asia-Pacific region is expected to grow in the global biohacking market with a healthy CAGR over the forecast period. The revamping healthcare sector with increasing investments in it contributes to the growth of biohacking market in Asia-Pacific. Europe has significant growth opportunities in the global biohacking market. The rising research and development in Europe drive the growth of the biohacking market in Europe.

Get this Section as a Free Customization in the Report Along With a 30% Discount on the Study. https://www.infiniumglobalresearch.com/reports/customization/18407

"We Have Decided to Extend Our Support to the Industry on Account of Corona Outbreak by Offering Flat Discount 30% on All Our Studies and Evaluation of the Market Dynamics in Biohacking Amidst COVID-19"

Biohacking Market Coverage

Chapter - 1 Preface

=> Report Description

=> Research Methods

=> Research Approaches

Chapter - 2 Executive Summary

=> Biohacking Market Highlights

=> Biohacking Market Projection

=> Biohacking Market Regional Highlights

Chapter - 3 Global Biohacking Market Overview

=> Introduction

=> Market Dynamics

=> Porter's Five Forces Analysis

=> IGR-Growth Matrix Analysis

=> Value Chain Analysis of Biohacking Market

Chapter - 4 Biohacking Market Macro Indicator Analysis

Chapter - 5 Global Biohacking Market by Type

=> Inside Biohacking

=> Outside Biohacking

Chapter - 6 Global Biohacking Market by Product

=> Smart Drugs

=> Strains

=> Sensors

=> Other Products

Chapter - 7 Global Biohacking Market by Application

=> Genetic Engineering

=> Forensic Science

=> Diagnosis and Treatment

=> Synthetic Biology

=> Drug Testing

=> Other Applications

Chapter - 8 Global Biohacking Market by End-user

=> Forensic Laboratories

=> Pharmaceutical and Biotechnological Companies

=> Other End-users

Chapter - 9 Global Biohacking Market by Region 2019-2025

=> North America

=> Europe

=> Asia-Pacific

=> RoW

Chapter - 10 Company Profiles and Competitive Landscape

=>Thync Global Inc.

=> Moodmetric

=> InteraXon Inc.

=> Behavioral Tech.

=> Fitbit, Inc.

=> Apple Inc.

=> Synbiota Inc.

=> The ODIN

=> HVMN Inc.

=> Modern AlkaMe

=> Other companies

Chapter - 11 Appendix

=> Primary Research Findings and Questionnaire

Browse Complete Report@ https://www.infiniumglobalresearch.com/ict-semiconductor/global-biohacking-market

About Infinium Global ResearchInfinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes and non-profit/non-government organizations to meet their knowledge and information needs.

Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations and environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.

For more information on this press release visit: http://www.sbwire.com/press-releases/how-covid-19-is-transforming-the-biohacking-industry-major-key-players-thync-global-inc-moodmetric-interaxon-inc-behavioral-tech-fitbit-inc-apple-inc-synbiota-inc-the-odin-hvmn-inc-modern-alkame-1291749.htm

Read the original:
How Covid-19 Is Transforming the Biohacking Industry? Major Key Players: Thync Global Inc., Moodmetric, InteraXon Inc., Behavioral Tech., Fitbit,...

Read More...

Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy – GlobeNewswire

Wednesday, May 20th, 2020

Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma

Off-the-shelf NK Cell Product Candidate Derived from Clonal Master iPSC Line Engineered with Three Functional Components to Enhance Innate Immunity

SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Companys Investigational New Drug (IND) application for FT538, the first CRISPR-edited, iPSC-derived cell therapy. FT538 is an off-the-shelf natural killer (NK) cell cancer immunotherapy that is derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three functional components to enhance innate immunity: a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor; an IL-15/IL-15 receptor fusion (IL-15RF); and the elimination of CD38 expression. The Company plans to initiateclinical investigation of three once-weekly doses of FT538as a monotherapy in acute myeloid leukemia (AML) and in combination with daratumumab, a CD38-directed monoclonal antibody therapy, for the treatment of multiple myeloma.

We are very pleased to expand the clinical application of our proprietary iPSC product platform to multiple myeloma, where rates of relapse remain high, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. Clinical data suggest that deficiencies in NK cell-mediated immunity, which are evident even at the earliest stages of myeloma, continue to accumulate through disease progression. We believe administration of FT538 to patients can restore innate immunity, and that the anti-cancer effect of certain standard of care treatments, such as monoclonal antibodies, can be more effective when combined with the engineered functionality of FT538.

The three functional components of FT538 are designed to boost the innate immune response in cancer patients, where endogenous NK cells are typically diminished in both number and function due to prior treatment regimens and tumor suppressive mechanisms. In preclinical studies, FT538 has shown superior NK cell effector function, as compared to endogenous NK cells, with the potential to confer significant anti-tumor activity to patients through multiple mechanisms of action including:

The first-in-human, multi-center, dose-escalation Phase 1 clinical trial of FT538 is designed to determine the maximum tolerated dose (MTD) of three once-weekly doses of FT538 in up to 105 adult patients across four dose cohorts (100M cells per dose; 300M cells per dose; 900M cells per dose; and 1.5B cells per dose). The study will assess two treatment regimens: Regimen A as a monotherapy in patients with relapsed / refractory AML; and Regimen B in combination with daratumumab, an FDA-approved anti-CD38 monoclonal antibody, in patients with relapsed / refractory multiple myeloma who have failed at least two lines of therapy. In addition, the Company may initiate a third treatment regimen in combination with elotuzumab, an FDA-approved anti-SLAMF7 monoclonal antibody, in patients with relapsed / refractory multiple myeloma who have failed at least two lines of therapy starting at one dose level below the MTD of Regimen B. For all regimens, multiple indication- or dose-specific dose-expansion cohorts of up to 15 patients per cohort may be enrolled to further evaluate the clinical activity of FT538.

FT538 is the fourth off-the-shelf, iPSC-derived NK cell product candidate from the Companys proprietary iPSC product platform cleared for clinical investigation by the FDA. The Company has initiated clinical manufacture of FT538 at its GMP facility in San Diego, CA.

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company's product candidates and clinical studies, the Companys progress, plans and timelines for the clinical investigation of its product candidates, the therapeutic potential of the Companys product candidates including FT538, and the Companys clinical development strategy for FT538. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of difficulties or delay in the initiation of any planned clinical studies, or in the enrollment or evaluation of subjects in any ongoing or future clinical studies, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that results observed in preclinical studies of FT538 may not be replicated in ongoing or future clinical trials or studies, and the risk that FT538 may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

Read the original here:
Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy - GlobeNewswire

Read More...

Coronavirus: Parliament told there is ‘no evidence’ virus came from Wuhan laboratory – Sky News

Wednesday, May 20th, 2020

There is "no evidence" supporting conspiracy theories that the coronavirus originated in a laboratory in Wuhan, an expert has told parliament.

Claims that COVID-19 was created in a lab were amplified by Donald Trump earlier this month, although the president refused to offer any evidence or give specific details.

The coronavirus outbreak first emerged in the Chinese city of Wuhan last year and international blame around the pandemic has incited conspiracy theories about its origin.

Rumours linking the virus to the Wuhan Institute of Virology - based on geographic proximity, and without any endorsement from qualified epidemiologists - have circulated.

But speaking to the House of Lords science and technology committee on Tuesday, Professor David Robertson dismissed the conspiracy theory as "unlikely".

Following the president's comments, the US Secretary of State Mike Pompeo claimed there was a "significant amount of evidence" supporting the theory but, just two days later, admitted: "We don't have certainty."

:: Listen to the Daily podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker

Scientists have discovered that the coronavirus was 96% identical to coronavirus found in bats, one of the many animals sold at a Wuhan seafood market where it is suspected the virus jumped to humans.

British authorities believe it is highly likely the global pandemic is unconnected to the laboratory in Wuhan and was passed from animals to humans naturally.

"You have a virus that you think comes from an exotic species and then you have a wildlife market - that seems the most parsimonious explanation," Professor Robertson said.

He was asked whether a sample of the virus found at the Wuhan Institute of Virology - and thought to be about 40 to 50 years old - could have been behind the initial outbreak.

Professor Robertson, who is the head of viral genomics and bioinformatics at the University of Glasgow, firmly responded: "No, absolutely not.

"That's partly what has driven some of these conspiracy theories, is what is the chance they would have this virus in the labs that is close? And actually, even though it is close in sequence, it is not close in time."

"There is really no evidence for this. We can all enjoy a conspiracy theory but you need to have evidence," he added.

Scientists have analysed the entirety of the novel coronavirus' genomic sequence to assess claims that it may have been made in a laboratory or been otherwise engineered.

The value of the genomic sequence could prove vital for those developing a vaccine, but it also contains key details revealing how the virus evolved.

Researchers at the Scripps Research Institute in the US, UK and Australia discovered that the virus has proved so infectious because it developed a near-perfect mechanism to bind to human cells.

This mechanism is so sophisticated in its adaptions that the researchers say that it must have evolved and not been genetically engineered in their paper, titled "COVID-19 coronavirus epidemic has a natural origin", published in the journal Nature Medicine.

Dr Josie Golding, the epidemics lead at the Wellcome Trust in the UK, described the paper as "crucially important to bring an evidence-based view to the rumours that have been circulating about the origins of the virus causing COVID-19".

"They conclude that the virus is the product of natural evolution, ending any speculation about deliberate genetic engineering," Dr Golding added.

The rest is here:
Coronavirus: Parliament told there is 'no evidence' virus came from Wuhan laboratory - Sky News

Read More...

Particle research could save wheat and other crops from deadly virus – New Food

Monday, May 18th, 2020

In a bid to protect wheat and other crops from the Brome Mosaic virus, scientists from UC Riverside set out to better understand how the virus particles interact with each other when infecting crops.

Brome Mosaic virus

University of California, Riverside scientists have announced that they have solved a 20-year-old genetics puzzle that could result in ways to protect wheat, barley, and other crops from a devastating infection.

Ayala Rao, professor of plant pathology and microbiology, has been studying Brome Mosaic virus for decades. Unlike some viruses, the genetic material of this virus is divided into three particles that until now were reportedly impossible to tell apart.

Brome Mosaic virus primarily affects grasses such as wheat and barley, and occasionally affects soybeans as well. According to Rao, it is nearly identical to Cucumber Mosaic virus, which infects cucumbers as well as tomatoes and other crops that are important to California agriculture.

Without a more definitive picture of the differences between these particles, we couldnt fully understand how they work together to initiate an infection that destroys food crops, Rao said. Our approach to this problem has brought an important part of this picture into very clear focus.

Inside each of the particles is a strand of RNA, the genetic material that controls the production of proteins. The proteins perform different tasks, Rao explained, some of which cause stunted growth, lesions and ultimately death of infected host plants.

Two decades ago, scientists used the average of all three particles to create a basic description of their structure. In order to differentiate them, Rao first needed to separate them, and get them into their most pure form.

Using a genetic engineering technique, Raos team disabled the pathogenic aspects of the virus and infused the viral genes with a host plant.

This bacterium inserts its genome into the plants cells, similar to the way HIV inserts itself into human cells, Rao said. We were then able to isolate the viral particles in the plants and determine their structure using electron microscopes and computer-based technology.

Now that one of the particles is fully mapped, it was said to be clear that the first two particles are more stable than the third.

Once we alter the stability, we can manipulate how RNA gets released into the plants, Rao said. We can make the third particle more stable, so it doesnt release RNA and the infection gets delayed.

Moving forward, Rao hopes to bring the other two viral particles into sharper focus with the expertise of scientists at UCLA and UC San Diego.

Not only could this research lead to the protection of multiple kinds of crops, it could advance the understanding of any virus, Rao added.

It is much easier to work with plant viruses because theyre easier and less expensive to grow and isolate. But what we learn about the principles of replication are applicable to human and animal viruses too.

See more here:
Particle research could save wheat and other crops from deadly virus - New Food

Read More...

Infectious Vaccines Partnering 2014 to 2020: Deal Trends, Players and Financials – PRNewswire

Monday, May 18th, 2020

DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

This report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals.

The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2014, including financial terms where available, including over 350 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since Jan 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Analyzing actual contract agreements allows assessment of the following:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/8txhqv

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Go here to read the rest:
Infectious Vaccines Partnering 2014 to 2020: Deal Trends, Players and Financials - PRNewswire

Read More...

After Covid-19, what is the future of conflict? Part 1 – TheArticle

Monday, May 18th, 2020

We fought two world wars in the 20th Century in defence of liberal values in this country. Then, after 9/11, we fought a series of engagements that attempted to impose those same values in other peoples countries. Now, the handle is turning again and even that recent aberration appears a long time ago. A new strategic epoch seems to indicate that we no longer need to go looking for a fight. Conflict will come to us.

The front line is no longer a nameless hillside in Afghanistan but the firewalls inside the computer systems of the power grid or what masquerades as news on social media. The digital revolution and globalisation have, in combination, dramatically increased the vulnerability of Western societies to severe disruption. We no longer have to speculate what a rupture of the distribution systems of the major supermarkets would look like. The creation of a black market in loo rolls at the start of the pandemic was a darkly comic moment but showed just how quickly the normal conventions of an apparently ordered society can unravel. And that wasnt even the result of a break in supply, but simply human frailty; what if the same systems were subject to a sophisticated and concerted cyber-attack?

Ever mindful that it might have to pick up the pieces, Lloyds Insurance conducted a recent study into the implications of a successful cyber-attack on 50 suppliers of the power grid covering the north east of America. It concluded that 93 million people would be without power immediately and for up to two weeks. During that time, and in the biting cold of a New York winter or the suffocating heat of a Washington summer, the immediate consequences of a blackout would be compounded by the secondary effects of opportunist crime and civil unrest, both of which would test the competence of government.

This is not an abstract, hypothetical threat the massive attack against Estonia in 2007 and the 2017 NotPetya malware attack against a variety of Western companies reveal cyber operations as a weapon of choice in contemporary conflict. And its not just the bad guys who are at it. The Stuxnet attack on the Iranian nuclear programme set the standard for cyber intervention and seemed to leave a trail back to America and Israel.

At the same time, Russian attempts to influence the outcome of the 2016 US presidential election by disinformation and fake news and even the faintly risible Iranian attempt to encourage Scottish separatism using the same methods during the 2014 referendum are a matter of public record. Cyber and information operations are being directed against this country on a daily basis in a form of conflict that is pervasive, insidious, ambivalent and rarely attributable. The attack on the Skripal family in Salisbury breathtaking in both its audacity and incompetence showed that chemical attack could also be part of contemporary conflict. What if, on the back of Covid-19, biological weapons became part of this sinister equation too?

Hittite texts written beyond 1000 BC speak of infiltrating people infected with deadly, communicable disease into rival communities in what is probably the first historical reference to biological warfare. The grotesque idea of using disease as an instrument in conflict has come and gone over the subsequent millennia and it was only in 1990 that Gruinard Island, off the west coast of Scotland, was declared safe after it had been used for experiments with weaponised anthrax in 1942. Today, an objective observer might see a Covid-19 death toll that will eventually run into millions, global economic dislocation and debt levels of individual nations that equate to multiples of GDP. These are conditions only normally associated with large scale conflict and is it entirely irrational for nation states, terrorist groups or even criminal organisations to ponder cause and effect?

In 2011, Dutch virologists working at the Erasmus Centre in Rotterdam caused a mutation of the H5N1 (bird flu) virus. Around the same time, research at the University of Wisconsin-Madison was working on grafting the H5N1 spike gene on to H1N1 swine flu virus. The mortality rate of bird flu is higher than 50 per cent and an animated academic debate ensued about whether both pieces of research should be published or whether the risk of rogue scientists replicating the work was too great. In the event, the research was published in Science and Nature respectively and is now available in the public domain.

So, bad stuff is out there, but the problem has always been in weaponising it in a way that creates mass dissemination, as the failed attempts of the Aum Shinriyko millenialist cult to use anthrax in Tokyo in the 1990s illustrated. Unfortunately, advances in genetic engineering and delivery techniques mean this challenge becomes ever more soluble and a determined programme could probably overcome the technical hurdles. If it did, a biological weapon would have a number of advantages over other forms of anonymised attack: even miniscule quantities can be lethal; symptoms can have delayed onset; and, subsequent waves of infection can manifest beyond the original attack site. The effect would be pervasive, insidious, ambivalent and perhaps unattributable exactly the fingerprints of contemporary conflict.

Lets go one step further and explore the very boundaries of rational action. Is it inconceivable that a state actor lets call it China for the sake of argument might contemplate a form of biological self-immolation? If it was confident in the ability of its large and compliant population to absorb an epidemic, its ubiquitous security and surveillance apparatus to impose control and with the advantage of foreknowledge, might it seek strategic advantage in creating a pandemic in the certain knowledge that strategic competitors would suffer far more?

It probably is inconceivable but not in the conspiracy-obsessed social media echo chambers that pass for news reportage among the more fevered parts of the American alt-right community. And so this article turns full circle: a piece of thin analysis and opinion feeds a conspiracy debate and adds to the dead weight of fake news that bends our sense of reality. Or, alternatively stated, this is what future conflict might look like.

The implications are profound and beg questions such as: what is now the point of nuclear weapons; how do we deter these forms of attack; and is a defence doctrine built around expeditionary operations and platforms like the Queen Elizabeth class of aircraft carriers remotely relevant to the future?

More here:
After Covid-19, what is the future of conflict? Part 1 - TheArticle

Read More...

Isaac Asimov: ‘How We’ll Live on the Moon’ – Popular Mechanics

Monday, May 18th, 2020

In March 1988, Popular Mechanics ran an article, written by sci-fi legend Isaac Asimov, exploring humanity's future on the moon. With NASA's plans to return to the moon in the coming years and President Trump's recent executive order clearing the way for companies to start mining the moon, Asimov's vision is more relevant than ever.

Reprinted here is the original article in its entirety.

Absolute silence.

The Lunarian stood in the eternal dark within the crater at the Moons south pole, and thought that silence was so characteristicand soothingand, yes, frighteningabout the Moon. He was not a true Lunarian, of course. He had come from Earth and when his 90-day stint was over, he would return to Earth and try to readjust to its strong pull of gravity.

There was no motion anywhere, no sound of living things. There was light along the crater top, as perpetual as the dark at this portion of the crater floor. Farther along the gently rolling floor, in the direction of the opposite side of the crater, was sunlight, too.

The Lunarian looked in that direction, and the photosensitive glass of his faceplate darkened at once.

The Lunarian thought: It is the year 2028 and the Moon has become our second world.

The line between dark and light swung slowly toward him and away in a 4-week cycle. It would never quite reach the point where he was standing, nor ever quite recede out of sight. If he were to move a few miles into the light, he would see the Sun skimming the crater edge along the horizon, but, of course, the faceplate grew virtually opaque if he accidentally looked in the Suns direction. At intervals, he could see the Earth, or a portion of it, edging above the crater wall. His heart would always melt at that sight. He tried not to think of Earth.

Pat Rawlins

For now, he was on the Moon. He could make out the line of photovoltaic cells in the sunlight and he knew that solar energy, never ending, was powering the world beneath his feetwhich was, as yet, very small. Already, dozens of human beings were housed there and in his lifetime it might well rise to hundreds. An experimental farm existed there, plus a chemical laboratory for the study of lunar soil, a furnace for baking out the small but precious amounts of volatile elements from appropriate ores.

This was not the only Moon base. A much larger one existed near the lunar equator, where the soil was mined and hurled into space to be used as a construction material. A much more specialized one existed on the Moon's far side where a huge radio telescope, insulated from Earth's radio interference by 2000 miles of solid Moon, was being completed.

The Lunarian thought: It is the year 2028 and the Moon has become our second world.

But it is now 1988. We have visited the Moon six times between 1969 and 1972, and 12 men have trod its surface. But those were visits only. We came, lingered and leftso that the total time human beings have spent on the Moon is less than two weeks.

But we have been sharpening our space abilities, and when we return to the Moon, it will be to stay. A day will come in the future after which there will never be a time when human beings will not be living on the Moon.

NASA is already planning Moon bases. In recent years, scientists, engineers, industrialists and scholars have met to discuss scientific, industrial and sociological issues in connection with living on the Moon. Former astronaut Dr. Sally K. Ride, America's first woman in space, recently produced a report outlining this nation's space goals. Satellite studies of the Earth will remain an important priority, along with the lofting of unmanned spacecraft to explore our solar system.

But the "Ride Report also stresses a manned permanent presence on the Moon before we embark on a manned mission to Mars, hoping to fully exploit the Moon's resources and scientific opportunities while boosting our own interplanetary learning curvebefore engaging in a Mars space spectacular.

Whether or not we choose to follow the Ride recommendations, the Moon will probably play an important role in man's future space explorations. But why bother? The Moon is a dead, desolate world, without air or water. It is a large super-Sahara. So what is there to make us want to go there, let alone live there?

Super-Sahara or not, the Moon would be useful, even vital, to us in many ways. Some of those ways are not material in nature. For instance, there is the question of knowledge. The Moon has not been seriously disturbed after the first half-billion years of the existence of the solar system (something that is not true of the Earth). We have been studying 800 pounds of Moon rocks astronauts retrieved, but merely bringing them to Earth has contaminated them, and the astronauts were only able to investigate isolated landing areas. If we can investigate the Moon's substance on the Moon, over extended periods and over every portion of its surface, we might learn a great detail about the early history of the Moon-and, therefore, of the Earth as well.

Unlike man's initial forays to the lunar surface, future trips to the Moon will be greatly aided by a space station positioned in low Earth orbit, by orbital transfer vehicles and by expendable lunar landers. It's envisioned that early lunar pioneers will reside in pressurized modules and airlocksnot unlike the modules currently being designed for the space station but with a significant difference. Because the Moon has no protective atmosphere, early settlers will cover their modules with up to 2 meters of lunar soil, or regolith, to protect them from solar radiation. These modules may give way to larger structures positioned beneath regolith archways or buildings made of lunar concrete as requirements change. Indeed, lunar building materials may one day be a principal lunar export.

Pat Rawlins

Solar collectors, photovoltaic systems and small nuclear powerplants positioned well away from lunar habitats would supply the power needs of an early Moon base. The resulting energy would support not only human explorers but a broad array of science and industrial activities, principally lunar mining and astronomical observation. Wheeled lunar rovers powered by the Sun would provide close-in transportation and cargo handling. Vertically launched rocket vehicles would aid in mapping and distant exploration. Some tasks may be performed by intelligent robots already on the drawing board.

After humans become established on the Moon, some visionaries foresee a complex of habitable dwellings and research labs for geochemical, physical and biological research. A life-giving atmosphere "manufactured on the Moon would promote ecological and agricultural pursuits, helping to make a Moon base self-supporting. Turning to the heavens, special detectors would analyze rays from astrophysical sources, and Moon-based particle accelerators would give new insight into the nature of matter. Spe cial units would process oxygen and refine new ceramic and metallurgical materials. "Moonmovers," adapted from Earthmovers, would excavate building and mining sites.

Think of the nuclear power stations we could build...where safety considerations did not bulk so large. Think of the efficiency of the solar power stations we could build on a world without an interfering atmosphere...

To what purpose? First, but not necessarily foremost, the Moon is a marvelous platform for astronomical observations. The absence of an atmosphere makes telescopic visibility far more acute. The far side of the Moon would allow radio telescopes to work without interference from human sources of light and radio waves. The Moon's slow rotation would allow objects in the sky to be followed, without interference from clouds or haze, for two weeks at a time. Neutrinos and gravity waves, together with other exotic cosmic manifestations, might be detected more easily and studied from the Moon than from the Earth. And, in fact, radio telescopes on the Moon and on the Earth could make observations in combination, allowing us to study in the finest detail the active centers of the galaxies, including our own Milky Way.

The Moon can also be used for experiments we would not wish to perform in the midst of the Earth's teeming life. Think of the genetic engineering we could perform, of the experimental life forms we could devise. We could obtain energy in copious quantities for use not only on the Moon, but for transfer to space structures and even to the Earth. Think of the nuclear power stations we could build (both fission and, eventually, fusion) where safety considerations did not bulk so large. Think of the efficiency of the solar power stations we could build on a world without an interfering atmosphere to scatter, absorb and obscure light.

Pat Rawlings

From the Moon's soil, we would obtain various elements. The Moon's crust is 40-percent oxygen (in combination with other elements, of course). This can be isolated. A common mineral on the Moon is ilmenite, or titanium iron oxide. Treatment with hydrogen can cause the oxygen of ilmenite to combine with the hydrogen, forming water, which can be broken up into hydrogen and oxygen.

But where would the hydrogen come from? Those portions of the Moon we have studied are lacking in the vital light elements: hydrogen, carbon and nitrogen. That makes it seem that these "volatiles will have to be imported from Earth (which has plenty), but there may be places where they can be found in small amounts on the Moon, especially in the polar regions where there are places where the Sun rarely shines. Lunar hydrogen can then be used to obtain oxygen, and lunar nitrogen can be used to dilute it. There you have an atmosphere.

Other elements, particularly iron, aluminum and titanium, all very useful structurally, are common in the lunar crust and can be smelted out of the soil. In addition, silicon can be obtained for making computer chips. The Moon will be an active mining base to begin with. Quantities of lunar soil can be hurled off the Moon by a "mass-driver, powered by an electromagnetic field based on solar energy. This would not be difficult because the Moon is relatively small and has a gravitational pull much weaker than that of Earth. It takes less than 5 percent as much energy to lift a quantity of matter off the Moon than it would to lift the same quantity off the Earth.

Pat Rawlings

To build observatories, laboratories, factories and settlements in space, it would make sense to use lunar materials, especially since Earthly resources are badly needed by our planet's population.

Because of the Moon's feebler gravity, it would be a particularly useful site for the building and launching of space vessels. Since far less power would be required to lift a vessel off the Moon's surface than off the Earth's, less fuel and oxygen would be needed and more weight could be devoted to payload.

Eventually, when space settlements are constructed, they may be even more efficient as places where space vessels can be built and launched, but the Moon will retain certain advantages. First, it will be a world of huge spaces and will not have the claustrophobic aura of the space settlements. Second, a lunar gravity, though weak, will be constant. On space settlements, a pseudo-gravitational field based on centrifugal effects may be as intense as Earth's gravitation in places, but will complicate matters by varying considerably with change of position inside the settlement.

The Moon, as an independent world, will represent a complete new turning in human history. Humanity will have a second world.

Then, too, since the Moon exists and is already constructed, so to speak, it can surely be developed first and be used to experiment with artificial ecologies.

Once the lunar colonists discover how to create a balanced ecology based on a limited number of plant and animal species (which may take awhile) that knowledge can be used to make space settlements viable.

Finally, of course, our Moon, with its enormous supply of materials, may eventually become a self-supporting, inhabited body in the solar system, completely independent of Earth. Surely this will become possible sooner than much smaller settlements elsewhere in space can achieve true independence.

The Moon, as an independent world, will represent a complete new turning in human history. Humanity will have a second world. If Earth should be struck by an unexpected catastrophe from without, say by a cometary strike such as the one that may have possibly wiped out the dinosaurs 65 million years agoor if humanity's own follies ruin Earth through nuclear war or otherwise then a second world will exist on which humanity will survive and on which human history, knowledge and culture will be remembered and preserved.

Asimov's Dream Coming True?

But when will this colonization take place? Naturally, we can't tell because so much of it depends not on technological ability but on unpredictable economic and political factors.

If all goes well, there is no reason why work on the project cannot be initiated in the 1990s. By 2005, the first outpost could be established, and by 2015, a permanently occupied Moon base may be in existence. After that, it may be that the Moon settlers will have developed their world to the point of being independent of Earth by the end of the 21st century.

On the other hand, if affairs on Earth are so mismanaged that there seems no money or effort to spare for space, or if humanity concentrates its efforts on turning space into a military arena and is not concerned with peaceful development or expansion, or if humanity ruins itself forever by means of a nuclear war in the course of the next few decades, then clearly there will be no Moon base, and perhaps no reasonable future of any kind.

View original post here:
Isaac Asimov: 'How We'll Live on the Moon' - Popular Mechanics

Read More...

Specialised Covid-19 detection lab inaugurated at SUST – The Daily Star

Monday, May 18th, 2020

A specialised laboratory for detecting Covid-19 was inaugurated today at Shahjalal University of Science and Technology (SUST) around 3:00pm.

Foreign Minister Dr AK Abdul Momen inaugurated the lab through a video conference. Textiles and Jute Secretary Lokman Hossain Miah, who is also coordinator of Sylhet district during the pandemic, and SUST Vice Chancellor Professor Farid Uddin Ahmed were present during the video conference, reports our Sylhet correspondent.

"We spent around Tk 1.09 crore from our own fund to buy new equipment including one new RT-PCR machine," Professor Farid Uddin said.

The lab has been installed at the Department of Genetic Engineering and Biotechnology of the university.

A group of teachers and students of the department will be dedicated in operating the laboratory with guidance from head of their department Professor Dr Md Shamsul Haque Prodhan.

"A new RT-PCR machine has been installed in the laboratory and the biosafety level (BSL) has also been upgraded to level 2. We also installed waste management system to manage hazardous waste," said Ziaul Faruque Joy, assistant professor of the department.

"A team of 20 will be running one cycle daily, testing up to 94 samples each day. This cycle will be doubled soon," he said.

The lab at Sylhet MAG Osmani Medical College was overwhelmed with samples waiting to be tested on the lone RT-PCR machine, prompting SUST to join the cause.

After the university showed interest, the Ministry of Health and Family Welfare on April 12 ordered its concerned division to take steps to initiate testing at the lab. The Directorate General of Health Services (DGHS) cleared the way on May 3.

More here:
Specialised Covid-19 detection lab inaugurated at SUST - The Daily Star

Read More...

Gene Therapy Market will Generate Massive Revenue to $4,402 million by 2023 | Novartis, Kite Pharma, GlaxoSmithKline, Spark Therapeutics – News…

Monday, May 18th, 2020

The global gene therapy market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023. Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patients cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.

Top Companies Covered in this Report: Novartis, Kite Pharma, Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc., Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica, NewLink Genetics Corp.

Get sample copy of Report at: https://www.premiummarketinsights.com/sample/AMR00013704

The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market.

The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Get Discount for This Report https://www.premiummarketinsights.com/discount/AMR00013704

Table Of Content

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: GENE THERAPY MARKET, BY VECTOR TYPE

CHAPTER 5: GENE THERAPY MARKET, BY GENE TYPE

CHAPTER 6: GENE THERAPY MARKET, BY APPLICATION

CHAPTER 7: GENE THERAPY MARKET, BY REGION

CHAPTER 8: COMPANY PROFILE

Enquire about report at: https://www.premiummarketinsights.com/buy/AMR00013704

About Premium Market Insights:

Premiummarketinsights.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us

Sameer Joshi

Call: +912067274191

Email:[emailprotected]

Pune

Visit link:
Gene Therapy Market will Generate Massive Revenue to $4,402 million by 2023 | Novartis, Kite Pharma, GlaxoSmithKline, Spark Therapeutics - News...

Read More...

Gene Editing Technologies in Diagnostic Platforms Market is expected to grow at a CAGR of 14.4% during the forecast period due to the rise in research…

Monday, May 18th, 2020

There has been a rise in government funding and research programs which is paving the way for the growth of the gene editing technologies in diagnostic platforms market. For example, the National Institutes of Health (NIH) has allocated funding on the study of clustered regularly interspaced short palindromic repeats (CRISPR) from 2011 to 2018. The NIH spent about US$ 3,083.4 million between the fiscal year 2011 and 2018 on a total of 6,685 projects. The funding has been increased by 213.1% between the fiscal year 2014 and 2015.

Request for Sample Copy of This [emailprotected] https://www.absolutemarketsinsights.com/request_sample.php?id=477

Moreover, with the help of NIH Common Funds support, National Institutes of Health (NIH) launched Somatic Cell Genome Editing (SCGE) program on January 2018 which is working to improve the effectiveness and specificity of gene editing techniques to assist in the diminishing of the burden of common and erratic diseases caused by genetic variations. The program aims at developing quality tools to execute and determine effective and harmless genome editing in somatic cells of the body. These tools will be made extensively available to the research community to lessen the time and expense which is required to develop new therapies. Furthermore, Somatic Cell Genome Editing program will award approximately US$ 190 million to biomedical researchers over the six years starting from 2018 till 2023. Hence, these types of research programs and funding given to the researchers will help the diagnostic platforms to get the tools which will aid them in carrying out gene editing and will drive the future market of the gene editing technologies in diagnostic platforms.

The number of CRISPR related publications, as listed in the SCOPUS database of peer-reviewed research, shows the surge in funding. Between 2015 and 2016, the number of such publications raised 117.5% which is 1,457. In 2019, the number surpassed 3,900 and increased at a rate of 4.8%. Overall, 12,900 papers associated with the technique have been published since 2011, Thus, this increasing research is expected to assist in the gene editing technologies in diagnostic platforms market growth over the forecast period.

Enquiry Before Buying @ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=477

The detailed research study provides qualitative and quantitative analysis of gene editing technologies in diagnostic platforms market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Key Findings of the Report:

In terms of revenue, the gene editing technologies in diagnostic platforms market is expected to reach US$ 7,004.8 Mn by 2027, expanding at 14.4% CAGR during the forecast period due to the rising government funding for genome editing and engineering

Beam Therapeutics, Bio-Connect Group, CRISPR Therapeutics, Editas Medicine, GeneCopoeia, Inc., GenScript, Horizon Discovery Ltd., Inscripta, Inc., Integrated DNA Technologies, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Merck KGaA, New England Biolabs, OriGene Technologies, Inc., Pairwise, Precision Biosciences, Sangamo Therapeutics, STEMCELL Technologies Inc., Thermo Fisher Scientific Inc., Transposagen Biopharmaceuticals, Inc. are the key market participants operating in the gene editing technologies in diagnostic platforms market.

Request for [emailprotected] https://www.absolutemarketsinsights.com/request_for_customization.php?id=477

Gene Editing Technologies in Diagnostic Platforms Market:

By Technology

CRISPR

TALEN

ZFN

Others

By Application

Cell Line Engineering

Genetic Engineering

Animal Genetic Engineering

Plant Genetic Engineering

Others

By End-User

Biotechnology & Pharmaceutical Companies

Academic and Research Institutions

Contract Research Organization (CROs)

By Geography

North America

U.S.

Canada

Mexico

Rest of North America

Europe

France

The UK

Spain

Germany

Italy

Nordic Countries

Denmark

Finland

Iceland

Sweden

Norway

Benelux Union

Belgium

The Netherlands

Luxembourg

Rest of Europe

Asia Pacific

China

Japan

India

New Zealand

Australia

South Korea

Southeast Asia

Indonesia

Thailand

Malaysia

Singapore

Rest of Southeast Asia

Rest of Asia Pacific

Middle East and Africa

Saudi Arabia

UAE

Egypt

Kuwait

South Africa

Rest of Middle East & Africa

Latin America

Brazil

Argentina

Rest of Latin America

Get Full Information of this premium [emailprotected] https://www.absolutemarketsinsights.com/reports/Gene-Editing-Technologies-in-Diagnostic-Platforms-Market-2019-2027-477

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Company: Absolute Markets Insights

Email id: [emailprotected]

Phone: +91-740-024-2424

Contact Name: Shreyas Tanna

The Work Lab,

Original post:
Gene Editing Technologies in Diagnostic Platforms Market is expected to grow at a CAGR of 14.4% during the forecast period due to the rise in research...

Read More...

New CRISPR method edits crops without technically making them GMOs – New Atlas

Monday, May 18th, 2020

CRISPR-Cas9 gene-editing is one of the most powerful tools available to modern science, but genetically-modified organisms (GMOs) in food are subject to some tight regulations. Now, researchers at North Carolina State University have created a new version of CRISPR that lets scientists edit crops without introducing new DNA, meaning they technically arent GMOs.

CRISPR-Cas9 allows for precise cut-n-paste edits to DNA in living cells. An RNA guide sequence directs the system to the target section of the genome. Once there, an enzyme, usually Cas9, snips out the sequence then deletes it or replaces it with something else. In this way, scientists can cut out problem genes, such as those that cause disease, or add new beneficial ones, such as giving crops better pest resistance.

For the new study, the researchers tweaked the process to make a cleaner edit in plants. It uses a process known as lipofection, where positively-charged lipids are used to build a kind of bubble around the Cas9 and RNA mechanisms. When injected into the organism, this bubble binds to and fuses with the cellular membrane, which pushes the CRISPR system into the cell itself. The method also uses a Cas9 protein itself, rather than the Cas9 DNA sequence.

The team tested the method by introducing fluorescent proteins into tobacco plants. And sure enough, after 48 hours the edited plants were glowing, indicating it had worked.

Wusheng Liu/NC State University

The new method has a few advantages over existing ones, the team says. Its easier to target the desired genetic sequence, and opens up new crops that couldnt be edited with existing methods. Plus, the protein only lasts for a few days before degrading, which reduces off-target edits.

But the most important advantage is that the resulting crops arent considered GMOs. Since the new method doesnt use Cas9 DNA, it doesnt introduce foreign DNA into the plant, which is an important distinction.

This was the first time anyone has come up with a method to deliver the Cas9 protein through lipofection into plant cells, says Wusheng Liu, lead author of the study. Our major achievement was to make that happen. Also, since many consumers prefer non-GMO specialty crops, this method delivers the Cas9 protein in a non-GMO manner.

As useful as genetic engineering can be, the term GMO has negative connotations for many people, who believe there are health concerns with eating these crops or meats. Other problems include the chance of modified plants or animals escaping into the wild, where they can spread their new genes to the native population, affecting ecosystems.

As such, the US Department of Agriculture (USDA) and the Food and Drug Administration (FDA) have regulations on which edited crops and animals are allowed in food. And theyve decided that the line is drawn at introducing foreign genes into an organism.

It makes sense. Humans have been genetically-engineering plants and animals for millennia, through selective breeding. Many of our most widely-eaten crops are bigger, tastier, and easier to eat or grow, to the point that they hardly resemble their wild counterparts anymore.

CRISPR and other gene-editing tools can be the next generation of this process. By removing problematic genes or ensuring that specific ones are turned on or off, scientists arent really creating anything new. Some individuals naturally have mutations that do the same thing all the scientists are really doing is removing the element of chance, genetically.

In 2015, a new type of salmon became the first genetically engineered animal approved by the FDA for human consumption. In 2016, a Swedish scientist grew, harvested and served up CRISPR cabbage after approval by the Swedish Board of Agriculture. In both cases, the products were allowed because they were functionally identical to wild-type organisms the scientists had just chosen beneficial genes from an existing natural pool, without introducing foreign DNA.

That said, the rules aren't the same everywhere. In 2018 the Court of Justice of the European Union somewhat controversially ruled that tough GMO laws applied to crops that had been edited even if new DNA hadn't been inserted. The issue will likely remain fragmented, but for the NC State team at least, their crops aren't GMOs according to their own country's regulations.

However, there are still some hurdles to overcome before the new method becomes viable. The team says that lipofection can only be done if the outer wall of the plant cell is removed first. This kind of plant cell, known as a protoplast, allows scientists to more easily tweak the genes, but it isnt possible in all types of crops, and even when it does work, its a complex process.

Instead, the researchers are exploring other options that dont require removing the cell wall at all. One such alternative is to use CRISPR to introduce the Cas9 protein into pollen grains, which can then go on to fertilize another plant. Some of the offspring will have the required genetic edits from day one.

The researchers plan to investigate this latter method in tomatoes and hemp first, before moving onto others.

The new study was published in the journal Plant Cell Reports.

Source: NC State University

More here:
New CRISPR method edits crops without technically making them GMOs - New Atlas

Read More...

How CRISPR can help us win the fight against the pandemic – MedCity News

Monday, May 18th, 2020

Covid-19 has changed life as we know it. It has also accelerated already rapid trends in innovation and collaboration across the scientific community.

As the pandemic spreads across the globe, researchers are racing to develop diagnostics, vaccines and treatments. In the pursuit of new solutions to tackle SARS-CoV-2, the novel coronavirus that causes Covid-19, researchers have been turning to machine learning, AI and high-throughput experimental automation that aid in development. Another powerful tool they are using to accelerate the process is CRISPR. This gene-targeting and gene-editing technology, based on the mechanism that bacteria naturally use to fight viruses, is already proving useful in our joint fight against this new virus.

CRISPR Advances Covid-19 TestingWe know early detection of SARS-CoV-2 is essential to isolating infected patients and managing appropriate healthcare responses. Recently, researchers at MIT published a rapid CRISPR-Cas13-based COVID-19 detection assay protocol.Since CRISPR can be modified to target nearly any genetic sequence, it can be used to detect SARS-CoV-2 RNA in a patient sample. This assay utilizes an RNA-targeting CRISPR nuclease to help scientists detect the SARS-CoV-2 RNA from patient samples within 60 minutes. More recently, an improved assay was developed by researchers at MIT that was shown to provide faster and more robust results.

Utilizing another CRISPR nuclease that is thermostable, they developed a test that in one step copies the viral RNA in a patient sample, such as saliva, into the more stable DNA and then specifically identifies a SARS-CoV-2 gene sequence. Performing this point-of-care assay requires minimal lab equipment and resources, as it only needs a few reagents and a heat source, delivering results in as little as 40 minutes. Supplementing existing tests with new CRISPR-based approaches can broaden accessibility to Covid-19 testing, a key strategy for stopping the spread through track and trace efforts, as outlined by the World Health Organization.

CRISPR Helps Engineer Future TreatmentsPreviously, the genome-engineering power of CRISPR has been directed at fighting genetic diseases. But more recently, its also being harnessed to fight infectious diseases, now including the new coronavirus.

Understanding how a pathogenic disease operates at the host-pathogen interface is critical to developing new treatments. CRISPR-based genome engineering enables researchers to study how SARS-CoV-2 interacts with human cells and generate the appropriate cell models that could lead to faster discovery of a potential new treatment or an existing drug combination that may provide a treatment solution. Once a potential treatment is identified, CRISPR makes the next step drug target screening more efficient, advancing us more quickly to a viable treatment option.

As an example of this approach in action, researchers are exploring if CRISPR can be used to verify the functional relevance of human genes recently identified to interact with SARS-CoV-2 proteins. The investigation of the molecular mechanisms of the novel virus can ultimately help identify drug combinations that have the best potential to treat those infected.

Current Fight for the Future of Human HealthGenome engineering has been rapidly harnessed by academic and non-profit institutions, the biopharma industry, and scientific pioneers to develop Covid-19 testing and treatment solutions. CRISPR-based genome engineering enables researchers to study how SARS-CoV-2 interacts with human cells and generate the appropriate cell models that could lead to faster discovery of a potential new treatment or an existing drug combination that may provide a treatment solution.

Beyond this, the unprecedented innovation taking place in response to the Covid-19 pandemic will provide a foundation for improving human health in the future. Additionally, as technologies and understanding mature, new approaches, such as engineered cell therapies, will become part of the toolkit in future responses to global health challenges.

The current scientific response is representative of the future of life sciences a future where we integrate multiple technologies and disciplines including high throughput experimental automation, machine learning and agile, programmable tools such as CRISPR to fundamentally change our approach to research and development. We are seeing a new bar being set on the speed of science as the research community comes together, leveraging these technologies to respond to the Covid-19 pandemic at unprecedented velocity. Once the public health crisis subsides and the research halted by the pandemic resumes, the need for these transformative tools, technologies and approaches to life science research and development will be greater than ever.

Photo: wildpixel, Getty Images

See original here:
How CRISPR can help us win the fight against the pandemic - MedCity News

Read More...

Innovative Virus Research May Save Wheat and Other Crops – SciTechDaily

Monday, May 18th, 2020

Visually indistinguishable particles of Brome Mosaic Virus. Credit: Ayala Rao/UCR

University of California Riverside scientists have solved a 20-year-old genetics puzzle that could result in ways to protect wheat, barley, and other crops from a devastating infection.

Ayala Rao, professor of plant pathology and microbiology, has been studying Brome Mosaic virus for decades. Unlike some viruses, the genetic material of this virus is divided into three particles that until now were impossible to tell apart.

Without a more definitive picture of the differences between these particles, we couldnt fully understand how they work together to initiate an infection that destroys food crops, Rao said. Our approach to this problem has brought an important part of this picture into very clear focus.

A paper describing the work Raos team did to differentiate these particles was recently published in the Proceedings of the National Academy of Sciences.

Inside each of the particles is a strand of RNA, the genetic material that controls the production of proteins. The proteins perform different tasks, some of which cause stunted growth, lesions, and ultimately death of infected host plants.

Two decades ago, scientists used the average of all three particles to create a basic description of their structure. In order to differentiate them, Rao first needed to separate them, and get them into their most pure form.

Using a genetic engineering technique, Raos team disabled the pathogenic aspects of the virus and infused the viral genes with a host plant.

This bacterium inserts its genome into the plants cells, similar to the way HIV inserts itself into human cells, Rao said. We were then able to isolate the viral particles in the plants and determine their structure using electron microscopes and computer-based technology.

Now that one of the particles is fully mapped, its clear the first two particles are more stable than the third.

Once we alter the stability, we can manipulate how RNA gets released into the plants, Rao said. We can make the third particle more stable, so it doesnt release RNA and the infection gets delayed.

This work was made possible by a grant from the University of California Multicampus Research Program and Initiatives. Professors Wiliam Gelbart,Chuck Knobler,and Hong Zhou of UCLA, as well as graduate students Antara Chakravarthy of UCR and Christian Beren of UCLA, made significant contributions to this project.

Moving forward, Rao is hoping to bring the other two viral particles into sharper focus with the expertise of scientists at UCLA and UC San Diego.

Brome Mosaic virus primarily affects grasses such as wheat and barley, and occasionally affects soybeans as well. According to Rao, it is nearly identical to Cucumber Mosaic virus, which infects cucumbers as well as tomatoes and other crops that are important to California agriculture.

Not only could this research lead to the protection of multiple kinds of crops, it could advance the understanding of any virus.

It is much easier to work with plant viruses because theyre easier and less expensive to grow and isolate, Rao said. But what we learn about the principles of replication are applicable to human and animal viruses too.

Reference: Genome organization and interaction with capsid protein in a multipartite RNA virus by Christian Beren, Yanxiang Cui, Antara Chakravarty, Xue Yang, A. L. N. Rao, Charles M. Knobler, Z. Hong Zhou and William M. Gelbart, 1 May 2020, Proceedings of the National Academy of Sciences.DOI: 10.1073/pnas.1915078117

Read more:
Innovative Virus Research May Save Wheat and Other Crops - SciTechDaily

Read More...

The great research mouse rescue amid the pandemic – WHYY

Monday, May 18th, 2020

This story is from The Pulse, a weekly health and science podcast.

Subscribe on Apple Podcasts, Stitcher or wherever you get your podcasts.

Back in mid-March, when most of us were hearing the words shelter in place for the first time, research labs across the country were busy with what they call saccing. Its short for sacrifice, like for science and the greater good.

There are a lot of different terms that are used that I think people use to protect themselves from the reality of this, said Anneka Allman, a research technician at a University of Pennsylvania lab that works with hundreds of mice as part of cancer studies. Personally, I prefer to say we kill them, but the common term is saccing.

Research mice, you might imagine, generally are not long for this world. At her lab, Allman is usually the one to send them into the hereafter. Most of the mice born there even in normal times arent suitable for experiments for some reason or another.

Id say maybe we only actually use like a tenth of the mice that we breed, Allman said. Euthanizing these mice on a regular basis is just part of the job, and its not a fun part of the job, but it is a necessity.

Still, what happened back in March, on Friday the 13th, it was different it was a massacre.

We have a weekly lab meeting and we had it virtually, and we were like, OK, we need to figure out how to shut everything down she recalled.

They had some 500 cages of mice, and a looming stay-at-home order for most staff. You just cant take that many mice home with you, and many cant survive outside sterile settings. So most of the mice, they were going to get sacced.

It was just like piles and piles of cages just on top of each other empty cages, Allman said.

She personally euthanized hundreds of the mice.

Its actually very simple. You take their cages, take off the tops, put it in a machine called the Euthan-X which I have a lot of feelings about, but its essentially just a CO2 chamber, Allman said. And you turn the button on, and you wait for 20 minutes to half an hour, and they die.

Allman only worked that Friday before she was sent home for safety, but a skeleton crew stayed behind and saccing continued.

We did get an email about, I think, two weeks in that basically requested that we stop asking them to do it because of the emotional toll that it was having on them because of the masses that they had to kill, Allman said.

The animals deaths didnt hit her on that level. Before you get the wrong idea about Allman, know shes a self-described animal lover, a vegetarian; one of her pet cats scurried across her laptop during an interview. But she didnt mourn the euthanized mice, so much as the science the mice represented.

I had to kill mice that I had planned experiments for, that Im still upset theyre dead and not because of their lives, unfortunately for them, but because to do this research its going to be a lot. Its going to take a lot longer.

Untold thousands of mice were sacced in the early weeks of the United States pandemic response. The animals in Allmans lab, and in hundreds of labs like it, are the bedrock of research into human diseases.

Pick a disorder, an illness. Theres a mouse model for that, a mouse created specifically to study that disease.

Cat Lutz is director of the mouse repository at the Jackson Laboratory in Maine.

So whatever disease you can think of, you know, epilepsy, obesity, metabolic syndrome, anything that you can think of, we have a mouse model that you can genetically engineer to recapitulate that particular disease, Lutz said.

The Jackson Lab is a nonprofit where many labs get founder mice to start colonies of their own for research. It has about 11,000 strains of designer mice cryopreserved in its repository 80% of which dont exist anywhere else.

Mice first found their way into labs by way of so-called mouse fanciers.

They would keep mice as pets, and they would also select those mice that had spontaneous mutations, for example, coat color or ears or craniofacial features, long tails, kinky tails, maybe spotted mice or things like that, and they would start inbreeding them, Lutz said.

Mice breed very quickly and very often, so mutations tend to spring up fairly regularly. Fanciers were after aesthetic mutations, but scientists quickly found fanciers could provide mice with more utilitarian mutations. This mouse with a kinky tail, it can develop diabetes, or colon cancer, or this rare neurological disease.

Between mouse and humans, the gene conservation is incredibly high at the level of the coding sequence, so it was really quite translational, Lutz said.

Mice and people share about 98% of their genetic code.

The mutations that you would see in the mice would often translate to the mutations that you see in people, she said. They really have become the model animal for humans.

So if you can cure a cancer in a mouse, thats a step closer toward curing it in a person.

Editors note: In a previous version of this story, the term saccing was misidentified. Saccing is short for sacrificing.

Read the original:
The great research mouse rescue amid the pandemic - WHYY

Read More...

When did coronavirus arrive in the US? Heres a review of the evidence – Economic Times

Monday, May 18th, 2020

By Mike Baker

SEATTLE: In a county north of Seattle, two people who came down with respiratory illnesses in December now have antibodies for the coronavirus. In Florida, a public health official who got sick in January believes he had COVID-19.

And in California, a surprising discovery that an early-February death in San Jose was linked to the coronavirus has triggered a broader search for how that person was exposed.

Those cases have contributed to growing questions about when the virus first reached the United States and how long it had been circulating by the time its arrival was publicly confirmed in Washington state at the end of February.

While there was limited testing to uncover specific cases before then, researchers have other tools to trace the path of the coronavirus. That includes genomic sequencing of the virus to help scientists build an ancestral tree of cases, a re-examination of specific deaths, and thousands of old flu samples that have been repurposed to look for coronavirus.

Heres a look at the evidence and what it shows:

Q: I got really sick in February. Did I have coronavirus?

A: Its possible, but it was most likely something else.

The Seattle area emerged as an early epicenter of the coronavirus outbreak at the end of February, but there is compelling evidence that, even there, the virus didnt yet have much of a foothold compared to the flu, which had a particularly potent season.

A team that analyzes flu trends in the region has been able to review nearly 7,000 old flu samples collected from around the region in January and February, re-examining them for coronavirus. All of the samples from January were negative. The earliest sample that tested positive was February 20.

Based on that and later case counts, Trevor Bedford, who studies the evolution of viruses at the Fred Hutchinson Cancer Research Center in Seattle, and who was part of the flu study team, estimated that there were probably a few hundred cases in the area by that point in February.

But even that would still be a small fraction perhaps less than 1% of the many thousands of people who had flu symptoms at the time.

Q: When did the coronavirus first reach the United States?

A: The U.S. first identified cases among travelers who had flown in from Wuhan, China, in the middle of January. Officials worked to contain them.

There is some evidence that the virus began getting a bit of traction around the end of January. To seed that late-February emergence in the Seattle area, researchers believe the spread could have begun with a traveler who arrived in the region from Wuhan on Jan. 15, or it may have been another unknown case that arrived in the few weeks that followed.

In San Jose, tissue sampling from a woman who died on Feb. 6 revealed that she was probably the first known person in the U.S. whose death was linked to the coronavirus a strong sign that the virus may have been circulating in that part of Northern California in January.

Q: But was it part of a large, previously unrecognized outbreak?

A: Dr. George Rutherford, a professor of epidemiology and biostatistics at the University of California, San Francisco, theorized that perhaps the woman, who worked for a company that had an office in Wuhan, was one of only a small number of people who contracted the virus at that time and that transmissions probably petered out for some reason. Otherwise, he said, the region would have seen a much bigger outbreak.

With that kind of early introduction, we should be seeing thousands of more cases, Rutherford said.

Dr. Sara Cody, the health officer for Santa Clara County, said local, state and federal officials were continuing to try to answer those questions.

There are other, less concrete signs of earlier infections. In Florida, where the first two official cases were announced on March 1, a state database now lists coronavirus cases in patients who may have had symptoms as far back as January. But the cases are all under investigation, and no one has confirmed that any of those patients had the disease that early.

One of them is Raul Pino, the health officer for the Florida Department of Health in Orange County. He said recently that he suspects he had the virus in the first week of January.

Q: What if the virus quietly arrived in December?

A: Doctors in France have said that a patients sample from late December has since tested positive for coronavirus. But so far, there is no comparable evidence of a similar case in the United States.

The strongest possible indicator so far is new evidence that emerged this week of two people in Snohomish County, Washington, who reported coronavirus-like symptoms in December. Both people later tested positive for antibodies, county health officials announced.

But Dr. Chris Spitters, the countys health officer, said that while it is possible that both people had the coronavirus in December even before officials in China had reported a cluster to the World Health Organization at the end of the month he is doubtful.

Its possible and frankly, I think, more likely that they had a non-COVID respiratory viral illness in December and subsequently had an asymptomatic or minimally symptomatic COVID infection subsequent to that, Spitters said.

Bedford said he also believed this was the more likely scenario, noting that up to half of people with coronavirus infections have no symptoms.

There could have been a tiny number of isolated coronavirus cases among travelers to the United States in December, Bedford said. But its pretty clear that none of them spread.

In part, scientists can tell that by looking at the genomic fingerprints of each case. But another clue is the rapid rate at which the virus spreads, said Rutherford.

It appears that early in the outbreak, one infection was spreading to about four other people, on average, with an incubation period for new infections of about four days. So a case seeded in December would rapidly quadruple through new generations, likely growing exponentially to millions of cases from a single unbroken chain of transmission by the end of February. Researchers arent seeing any chains that appear to go that far back.

Modelers looking back at the growth of outbreaks elsewhere have reached similar conclusions. One estimated that New Yorks outbreak could have begun with perhaps 10 infected people who contracted the virus sometime between the end of January to the middle of February, when the first cases of community transmission were identified and hospitals began seeing more cases.

Q: When did the virus begin in China?

A: The virus first emerged in Wuhan in December after a series of people developed symptoms of a viral pneumonia and an examination found that they had been infected with a new coronavirus.A group of researchers in China later examined the histories of the first 41 lab-confirmed cases at a Wuhan hospital, finding that many of them had connections to a seafood market. But the earliest case, in a person who developed symptoms on Dec. 1, had no connections to the market.

The information suggests that if the virus did originate from the market, it was likely circulating by November, early enough to reach that first person. Bedford said it was conceivable to him that the virus began as early as October, but that November was more likely.

There is no evidence that it started elsewhere. The virus mutates an average of twice a month, something researchers can see in the genomic sequences of individual cases, and all of the cases in Wuhan show close genetic links.

All the other thousands of cases that have been sequenced around the globe show the Wuhan version as an ancestor.

Q: Was the coronavirus made in a lab somewhere?

A: Several unfounded theories that have gained traction suggest that the virus was created or accidentally released in a lab somewhere. The Chinese government speculated that perhaps Americans brought the virus in to China. President Donald Trump has suggested it came from a virology lab in Wuhan.

Bedford said there is no evidence of genetic engineering in the virus, noting that it appears to be a genetic outgrowth of a virus circulating among bats. It likely reached humans through an intermediate animal, such as a pangolin, he said.

Theres no hallmarks of it having been manipulated in a lab, Bedford said. I think thats definitive.

He did not, however, rule out the possibility that some version of the virus being studied by scientists in Wuhan could have somehow escaped and spread from there. But he doubts that is the case. He said that the most prevalent theory about the viruss origins, that it spread naturally among animals at a live animal market in Wuhan, then jumped to humans, is the most likely explanation.

Follow this link:
When did coronavirus arrive in the US? Heres a review of the evidence - Economic Times

Read More...

Why Ethiopia needs to embrace gene-modification technology – ethiopiaobserver.com

Monday, May 18th, 2020

The recent exchanges on Ethiopias acceptance of genetically modified (GM) crops and the resulting report of USDA praising the steps our country has taken continue to be informative. My understanding of the debates surrounding GM foods suggests that neat explanations about their usefulness grossly disregard the muddy footprints and messy stories of the technology while the voices of vilification and blanket rejection tend to thrive more on emotional appeal than rigorous science. Lets start with the basics.The 21st century is said to be the century of biology and ecology. Thus, for Ethiopia, as one of the globes top 50 centers of biodiversity, where better to capitalize on than in understanding and developing its crop and animal varieties and fulfill its long-held potential of being Africas breadbasket. Ethiopia is one of the few centers where domestication of crops was practiced at the dawn of agriculture and the country has contributed to the worlds collection of cultivable species such crops as Teff, coffee, enset, sorghum, millet, etc. It means that our farmers are not new to the genetic modification of organisms since every domestication effort involves selective breeding and recombination of desired characteristics. We also have adopted several foreign plant species (maize, wheat, barley, tomatoes, potatoes, pepper, etc.) some of them only a few centuries ago, without much consideration for their effects on our indigenous species.Despite these impressive records, our agricultural system stayed firmly rooted in its ancient practices which suffer from abysmal efficiency and very poor productivity. As a result, Ethiopia remains a net importer of crops both for human consumption and for its expanding industries, and there seems to be no natural end to this depressing trend. The consequence is not only a shrinking of profit base for many of the industries but also the misplaced use of the meager hard currency obtained from the export of some raw materials with all the negative impacts on our capacity in importing more useful technologies.

Ironically, Ethiopia has no shortage of cultivable/irrigable land or population able or willing to participate in modern agricultural practices. In fact, Ethiopias farming community is estimated to be above 80% of the population but is unable to feed itself properly let alone supply raw materials for the manufacturing sector. The production by small scale farmers in Ethiopia is demonstrably incapable of keeping pace with the population growth as tens of millions of our people still depend on food handouts every single year and many more live in precarious situations. Therefore, it is pertinent that the country becomes self-sufficient at least for feeding the population with all possible means. And, this is not a very hard task given the scale of its cultivable land and the disproportionately large population whose livelihood is dependent on farming.The most relevant question is thus how to end this absurdity and persistent tragedy without drastically affecting the livelihood of our farmers and disrupting the biodiversity balance. For a very long period of time, Ethiopia lacked the capacity to introduce mechanized farming and other relevant agricultural technologies. Further, it lagged far behind many (African) countries in developing its policies and relevant practices with regard to the application of plant genetic engineering technology. Arguably the most unhelpful effort on part of the Ethiopian government in the last decade has been the introduction of the Biosafety Proclamation No. 655/2009. It is possible that this proclamation was enacted as a genuine effort to protect the local farmers and the countrys agriculture sector from control by a few foreign biotech industries and create a formidable safeguard against potential fallouts from untended consequences of releasing GM crops. However, it is clear from the outset that the proclamation lacked proper scrutiny by all the relevant stakeholders, not least farmers representatives or experts from agricultural research centers in the country. In addition, it failed to recognize the potential of local agro-biotechnology research and innovation and was oblivious to the rapidly changing focus of the debate and policy shifts surrounding this emerging technology from around the world. Thus, our Biosafety Proclamation No. 655/2009 was, by international standards, relatively outdated as soon as it was hastily passed by the parliament (hence the justification for a later amendment as Proclamation No. 896/2015).It is unclear why modern GM organisms are so divisive and treated as highly toxic materials that should be feared and avoided at all costs. Rigorous analysis done by scientific institutions such as the UK Royal Society and the U.S. National Academy of Sciences has demonstrated that such organisms are at least as safe as their counterparts produced by conventional breeding techniques. For example, the GM cotton that Ethiopia is said to have started cultivating is the widely known Bt variety. In short, Bt is abbreviated from Bacillus thuringiensis, a bacterium species that naturally occurs in soil and produces highly specific insecticidal proteins. This bacterium has been in use, in one form or another, as the most effective, naturally occurring, and environmentally friendly bioinsecticide for more than half-century. Bt spray is currently the dominant bioinsecticide in the world and is authorized for use even by organic farmers worldwide. Therefore, we are talking about a well-characterized gene of a bacterium (which might as well be dwelling in our soils all along). Plants expressing this gene have been tested for more than two decades in several countries and in a wide range of ecological settings for the properties they have been designed for, with no confirmed case of ill effect as food or feed.I suspect that Ethiopia has been misled or pressured into adopting an overly cautious interpretation of the precautionary principle as was the case in the past in some EU countries. In my opinion, the EU and its policies on GM products (even as progressive as they currently are) cannot be a good lead for Ethiopia. For one, farming practices in the EU are already highly productive even without the need for the introduction of GM. In addition, the sheer proportion of the population involved in the agricultural sector in Ethiopia means that unreasonable restrictions on agricultural biotechnology can have far-reaching consequences. For Ethiopia, the better place to look for inspiration is other developing countries around the world in Latin America, Asia, and in the continent of Africa itself for our capacities and needs are likely to be similar.

India, for example, started commercial farming of Bt-cotton in 2002 and at the moment, about 25% of its agricultural land is covered with this variety, the highest proportion in the world. In our continent, South Africa is the pioneer in providing permits for the commercial cultivation of GM crops for GM cotton and maize starting in 1997. Egypt has been commercially farming Bt-maize hybrid since 2008, using seeds procured from South Africa (it has since suspended the cultivation due to the lack of proper biosafety laws and other local issues). Ghana, Nigeria, Cameroon, and, our neighboring countries, Sudan, Kenya, Uganda, Tanzania, and Mozambique have all tested and/or adopted the cultivation of GM crops. Furthermore, Nigeria, Kenya, and Uganda are pursuing various genetic modifications to the cassava plant, a staple crop for over half a billion people around the world. It is disingenuous, to say the least, to assert that all of these countries are either threatened or duped into accepting this technology to the detriment of the wellbeing of their population and ecosystems.Ethiopia, on the other hand, despite having several, experienced agricultural research institutions, is missing out for far too long on the development of its genetic research capacity and utilization of available biotechnologies, especially as compared to many of these African countries. As a commentary on this site made it clear, the Ethiopian team negotiating the Cartagena Protocol, led by Dr. Tewolde-Birhan Gebre-Egziabher, played a key role in formulating a strong African position and had become the continents de-facto representative. This had been appreciated and acknowledged by several African countries at that time. Whether this fact can make Ethiopia assume a Pan-Africanist leadership position in the environmental issues is completely irrelevant to the issue at hand. What is important is the fact that the Cartagena Protocol aims mainly to provide an adequate level of protection to worldwide biodiversity by placing a stringent control on the transboundary movement, transit, handling and use of all living modified organisms that may have adverse effects on the conservation and sustainable use of biological diversity. What it is not is an outright ban on the development, test or use of GM organisms for food or feed. In addition, several of the major African countries have since moved on and have come to realize that application GM crops, transgenic technology, and genetic engineering know-how could have a transformative effect on parts their economies provided that these are supported by a strong monitoring regimen. As a result, and contrary to its supposed pan-African leadership, Ethiopia is currently an outlier in the continent when it comes to the exploration of this powerful technology that can potentially transform the living standards of millions of people. Many of the countries that are said to be hesitant in accepting this agricultural biotechnology lack either the capacity to adapt and manage it or the actual need for a rapid transformation of their agricultural practices (they are either food self-sufficient or have no industrial base to supply to or both). In other words, we may as well have once been the continents leading voice against GM organisms but it has become apparent that we are leading the wrong league and it is not where we belong it is unbecoming to our great nation.What Ethiopia urgently needs is a dynamic regulatory system and strong scientific capacity for the evaluation, authorization, and monitoring of imported GM crops. It also needs to rebuild and expand its capability for fundamental research with the aim of developing local GM species using state-of-the-art methodology. Public-private biotechnology partnerships should be encouraged to work on genetic identification and improvements even in our own indigenous species of plants and animals. Furthermore, since we are negotiating for accession to the World Trade Organization, it is the most relevant time to substantially revise or repeal the Biosafety Proclamation No. 655/2009 (including its latest incarnation, Proclamation No. 896/2015) and streamline other relevant laws in accordance with international standards.

To this writer, the question is not to be why Ethiopia allowed the commercial cultivation of Bt-cotton and has authorized a confined field trial of Bt-maize. It is whether it had conducted a thorough analysis of the existing problems in the sector and identified the effectiveness of these particular strains of GM crops as cost-effective and sustainable solutions. It is not a case of re-inventing the wheel but of identifying our desirable targets and requirements, learning from the front-runners, and applying an appropriate level of precautionary principles. The temporary setbacks in Burkina Faso, Africas largest producer of cotton at one point, and some regions in India demonstrate that the process of introducing GM crops is far from being a turn-key situation. It requires the collaboration of laboratory scientists, policymakers, market leaders, and farmers (end-users) in identifying the required crop characteristic and quality that is suitable for the specific condition of the locality.In conclusion, agricultural gene-modification technology has sufficiently demonstrated its worth after more than two decades of commercial application and this is reflected in its widespread global adoption.Therefore, the excessive hesitance of its acceptance by Ethiopia and campaigners that support this stance is unjustifiable either socially, economically, or more importantly, scientifically.

Main Image: Children at a farm in Hawzen, Tigray region. Ethiopia Observer file.

This article is published under aCreative Commons Attribution-NonCommercial 4.0 International licence. Please cite Ethiopia Observer prominently and link clearly to the original article if you republish. If you have any queries, please contact us at ethiopiaobserver@protonmail.com. Check individual images for licensing details.

View original post here:
Why Ethiopia needs to embrace gene-modification technology - ethiopiaobserver.com

Read More...

Mystery of SARS-CoV-2 genome isolated in Bangladesh – The Daily Star

Monday, May 18th, 2020

SARS-CoV-2 has so far infected more than 4,500,000 people in 187 countries and caused over 300,000 deaths, but no drug or vaccine is yet available. In Bangladesh, over 20,000 people have been infected and 250 died. Lockdown can provide a temporary solution but we need a sustainable solution for this.

Although there are three (A,B,C) SARS-CoV-2 variants, we still don't know which one is prevailing in our country, how and through which route it has been transmitted here; if it has acquired any mutations by now and how deadly it has become. Also, we do not know why some people are affected more, showing serious symptoms, while others remain asymptomatic. We do not know why and how this has created serious havoc in some countries whereas others are only mildly affected.

In the modern era, problems in biological sciences are tackled by a bottom up approach, where we do genome sequencing of the relevant organism and associate it with other metadata to address the problem and find solutions. For the same reason so far 80 countries have deposited more than 24,000 genome sequences of this virus, which includes even countries like Nepal and Vietnam where the coronavirus problem is comparatively less severe. Since the first cases were reported on March 7, 2020 by the country's epidemiology institute IEDCR, we have been repeatedly advocating the need for genome sequencing of this virus. We also ensured that we make substantial advancement in science and technology, especially with the special attention of the prime minister in this sector.

Now we are able to do genome sequencing by Next Generation Sequencing (NGS) in our country. There are some institutes and private organisations where NGS machines are available and virus genome sequencing can be done, and also we have expert and experienced Bioinfomaticians who can perform complete genome sequence analysis. The ground-breaking work has finally been done by the Child Health Research Foundation (CHRF). Dr Senjuti Shaha and Dr Samir Kumar Shaha, along with their team from CHRF, collected samples from a 22-year-old coronavirus infected female patient and arranged to do whole genome sequencing of the virus using Illumina iSeq 100 NGS platform. As soon as the news of deposition of genome sequence data became available on May 12, Tuesday afternoon, we sought to extract this sequence and information from the public repository GISAID and CNCB, and started to explore it.

Lead by me at the Department of Genetic Engineering and Biotechnology, University of Dhaka, the Epigenetic and Bioinformatics team on nCoV research has done basic analysis of the genome. My team member Mr Abdullah Al Kamran Khan was with me in this analysis. We compared the sequence with that of the first reported coronavirus genome sequence from Wuhan, Chinawhich is globally considered as "reference". Strikingly, we have found that this genome is very similar (99.7 percent similarity) to that of reference SARS-CoV-2 isolated from Wuhan. There are changes only in nine places and these changes are single nucleotide change (SNP). There are no deletion or insertion/addition of any large sequence compared to the original reference.

However, with great surprise, we observed that this genome has acquired two new mutations which have not been seen among the viruses reported so far and that we have observed closely. At position 1163 (genes orf1ab) a new mutation from A to T has been detected. Previously at the same position nucleotide A to C in one virus and nucleotide A to G changed in another genome reported. Also, there is a brand new mutation position at 17019 detected in our Bangladeshi isolated virus which has not been reported so far. This means that these are the new changes that the virus has acquired after entering into Bangladesh. Out of nine, seven other mutations were very common among the sequenced viruses so far. We can further study what trouble or benefit these new mutations have brought us.

Very interestingly, of these nine mutations, it contains a mutation (Single Nucleotide Mutation or SNP) in its Spike protein. There is non-silent (non-synonymous), amino acid changing (Aspartate to Glycine) mutation at the 614th position of the Spike protein (D614G). This is of particular interest because it is probably due to this mutation that the virus could spread quickly among the European and American populations compared to the original virus from China. This creates an additional serine protease (Elastase) cleavage site near the Open Reading Frame (ORF) S1 and S2 junction of the Spike protein.

The interesting aspect is that in human, a single nucleotide mutation (deletion of C nucleotide, delC) (rs35074065 variant site) in the TMPRSS2 receptor gene facilitates the entry of SARS-CoV-2 with D614G mutation to the cell very effectively. Dr Hemayet Ullah from Howard University, USA, also informed us that this delC mutation is very common in the American and European population but very rare in the East Asian/Asian populationshence the change of amino acid aspartic acid to glycine in the S protein of the virus may be helpful for Asian countries but more infectious in the American and European populations. We do see a less severe effect in Asian countries compared to that in Europe and America. Any deleterious mutation from the perspective of an organism gets lost through natural selection and we hope more virulent mutation does not appear in Asian countries later on. Several research papers are also available on this mutation.

To understand the origin, we have constructed phylogenetic tree (UPGMA and Neighbour-Joining) in MEGA with default parameters, with representative sequences from 60 other countries and the reference sequence, totalling 350 sequences. Phylogenetic tree shows that this Bangladeshi SARS-CoV-2 genome isolate seems closer to European clustermost likely the person got infected from someone who returned from Europe or maybe she herself returned from there. We are fine-tuning the phylogenetic tree. And are also in the process of making phylogenetic tree with 10,000 high quality sequences selected from 80 countries to better explain the origin and route of transmission of this particular virus.

To understand the pattern of infection in Bangladesh, only one genome sequence is not enough. We need sequence of at least 100 isolates. We have made a proposal to the ICT ministry in response to their "Call for Nation (Hakathon)". In this study proposal we aim to create a dataset by combining 100 coronavirus genomes from Bangladeshi patients and integrate this genome information with patient's personal/clinical/treatment/diagnostic and other information. This information will be analysed extensively by computational methods to do clustering, phylogenetic and pharmacogenomics studies, and will compare data with other globally available data to make a concrete information-base that will help pharmaceutical industries produce appropriate drugs and vaccines for our population.

Also, the ICT ministry will be able to announce that Bangladesh has uncovered the genome mystery of the coronavirus circulating in the country and trace back the transmission. This project will be a multicentre research where essential help from ICT/Bangladesh government, and help of IEDCR through the government will be required to get patients' samples and relevant clinical data. We will carry out sequencing (Next Generation Sequencing) of the viral genome and other analyses with our own resources in Bangladesh. If ICT/government support us, it is also possible to do further research in future where in addition to the viral genome we can sequence genome of some individuals who were infected and developed the disease as well as healthy individuals who did not develop the disease. This may also let us know the factors (if any) that conferred resistance to them.

Dr ABMM Khademul Islam, associate professor, Genetic Engineering and Biotechnology, University of Dhaka.

Read more from the original source:
Mystery of SARS-CoV-2 genome isolated in Bangladesh - The Daily Star

Read More...

Scientists Find New Way to Inject Plants With Medicine, And It May Help Save Our Crops – ScienceAlert

Monday, May 4th, 2020

You may not think of plants as needing life-saving medicine, but that's sometimes the case when bugs and disease strike. Now, scientists have developed a super-accurate, highly delicate way of delivering drugs, and right where plants need them.

At the moment, plants can be sprayed with pesticides, which doesn't really penetrate to the roots, or they can be treated with large needles that aren't particularly precise, and tend to cause damage to the plants.

The new method makes use of microneedles or what the researchers are calling 'phytoinjectors', sitting on top of a silk-based biomaterial patch, which are able to hit a plant's circulatory system directly. Pesticides, in contrast, might travel between the root system and the leaves.

(Cao et al., Advanced Science, 2020)

As well as delivering medicine or nutrients to different parts of the plant, the new mechanism could also be used to take samples of a plant, which are then transferred to a lab for analysis, or even to edit DNA (something the team has successfully tried).

"We wanted to solve the technical problem of how you can have a precise access to the plant vasculature," says mechanical engineer Yunteng Caofrom MIT.

"You can think about delivering micronutrients, or you can think about delivering genes, to change the gene expression of the plant or to basically engineer a plant."

The motivation for the project came from the spread of the citrus greening disease across the US and other parts of the world, which threatens to flatten an industry worth $9 billion if a solution isn't found. Olives and bananas are other fruits under particular threat from disease across the world right now.

Previous work looking at the use of microneedles to deliver human vaccines was used as a starting point, with silk kept as the basis of the material holding the microneedles.

Silk is strong, doesn't cause a reaction in plants, and can be made degradable enough to get out of the way once the drugs have been delivered.

However, a lot also had to change compared to microneedles used on humans: plants have far less water available than the human body does, so the design had to be adapted.

The team of scientists was able to boost the silk's hydrophilicity (water-attracting capabilities), and come up with a new material more suited for plants.

"We found that adaptations of a material designed for drug delivery in humans to plants was not straightforward, due to differences not only in tissue vasculature, but also in fluid composition," says biologist Eugene Lim.

Tests of the material and its microneedled payload on tomato and tobacco plants showed that it could be successful as a drug delivery system. Fluorescent molecules were used to track the progress of the injection all the way from the roots to the leaves.

The system should adapt to other plants fairly easily, the researchers say, though scaling it up is going to prove more challenging. The work should prove useful for future projects though, both in delivering life-saving drugs to save plants from disease, and in engineering them to avoid disease in the first place.

"For the future, our research interests will go beyond antibiotic delivery to genetic engineering and point-of-care diagnostics based on metabolite sampling," says environmental engineer Benedetto Marelli.

The research has been published in Advanced Science.

Visit link:
Scientists Find New Way to Inject Plants With Medicine, And It May Help Save Our Crops - ScienceAlert

Read More...

Page 17«..10..16171819..30..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick